JOURNAL ARTICLE

Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.

  • Published In: Clinical & Experimental Dermatology, 2024, v. 49, n. 8. P. 817 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Zhao, Chenjing; Yu, Meiwen; Cheng, Xianfeng; Li, Suo; Feng, Suying 3 of 3

Abstract

This article investigates the association between coagulation factor X and livedoid vasculopathy (LV), a chronic thrombotic skin disease, and evaluates the efficacy and safety of rivaroxaban, a factor Xa inhibitor, in treating LV. The study found that patients with LV exhibited significantly higher coagulation factor X activity compared to healthy controls, particularly during the progressive stage of the disease. In a treatment cohort, rivaroxaban led to complete remission of ulcers in 91% of patients and retiform purpura in 73% within 12 weeks, with mild side effects reported in 25% of patients. These findings suggest that coagulation factor X activity is linked to LV severity and that rivaroxaban is an effective and safe therapeutic option for managing ulcers and retiform purpura in LV.

Additional Information

  • Source:Clinical & Experimental Dermatology. 2024/08, Vol. 49, Issue 8, p817
  • Document Type:Article
  • Subject Area:Science
  • Publication Date:2024
  • ISSN:0307-6938
  • DOI:10.1093/ced/llae023
  • Accession Number:178928283
  • Copyright Statement:Copyright of Clinical & Experimental Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.